Salma Saiger, MD
Internal Medicine · Mesquite, TXNPI 1487690855
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,871 of the $9,142 with a category attached, or 86.1%. It is spread thinly across 38 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 451 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1K
- Novo Nordisk$931
- AstraZeneca$927
- Janssen Research & Development, LLC$709
- AbbVie$643
- Merck$549
- plus $4K from 32 others
Across 1,253 payments — averaging $12,874 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10.2M
- Partner Therapeutics, Inc.$1.1M
- Janssen Research & Development, LLC$805K
- Sanofi US Services Inc.$705K
- Bavarian Nordic A/s$673K
- GSK$510K
- plus $2.1M from 22 others
What the payments were for
- Travel & lodging$1,23313%
- Food & beverage$7,87186%
- Education$180%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 3 | $1,436 |
| Novo Nordisk | 59 | $931 |
| AstraZeneca | 57 | $927 |
| Janssen Research & Development, LLC | 9 | $709 |
| AbbVie(2 entities) | 41 | $643 |
| Merck | 44 | $549 |
| Lilly USA, LLC | 32 | $509 |
| GSK | 25 | $400 |
| Amarin Pharma, Inc. | 23 | $376 |
| Boehringer Ingelheim | 22 | $359 |
| Bayer | 22 | $355 |
| Amgen | 19 | $342 |
| Pfizer | 21 | $296 |
| Abbott | 12 | $218 |
| Johnson & Johnson | 9 | $131 |
| Teva Pharmaceuticals USA, Inc. | 8 | $120 |
| Corcept Therapeutics | 3 | $113 |
| Ironwood Pharmaceuticals, Inc | 5 | $82 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Dexcom, Inc. | 3 | $52 |
| Exact Sciences | 3 | $50 |
| Astellas Pharma US Inc | 3 | $49 |
| Novartis | 2 | $41 |
| Currax Pharmaceuticals LLC | 3 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $28 |
| Sanofi | 1 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Shield Therapeutics Inc | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Stryker | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Optos, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
How this compares
$9,142 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $197,225 |
| JardianceEmpagliflozin | 106 | $159,940 |
| FarxigaDapagliflozin Propanediol | 105 | $142,133 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $120,016 |
| RybelsusSemaglutide | 61 | $119,756 |
| EliquisApixaban | 44 | $60,943 |
| MounjaroTirzepatide | 42 | $50,322 |
| JanuviaSitagliptin Phosphate | 35 | $49,776 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $43,792 |
| CreonLipase/Protease/Amylase | 15 | $27,348 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $26,901 |
| ProliaDenosumab | 14 | $25,048 |
| BelsomraSuvorexant | 25 | $23,057 |
| TradjentaLinagliptin | 27 | $23,026 |
| VascepaIcosapent Ethyl | 36 | $22,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $931 | $316,981175 claims |
| Boehringer IngelheimJardiance, Tradjenta | $359 | $182,965133 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $927 | $162,163118 claims |
| GSKTrelegy Ellipta | $400 | $120,016102 claims |
| MerckJanuvia, Belsomra | $549 | $72,83360 claims |
| PfizerEliquis | $296 | $60,94344 claims |
| Lilly USA, LLCMounjaro | $509 | $50,32242 claims |
| AbbVieCreon | $643 | $27,34815 claims |
| AmgenProlia | $342 | $25,04814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Mesquite
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.